Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeLatest news

      Latest news

      Inside the development of a revolutionary treatment for blood cancers

      In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.

      How robots are helping personalize knee replacement surgery

      For Arthritis Awareness Month, learn the latest about this common procedure and how Johnson & Johnson MedTech is innovating to improve patient outcomes.

      More from Johnson & Johnson

      4 things to know about Johnson & Johnson’s 2023 Health for Humanity Report

      The annual report details the company’s ongoing work in helping to create a healthier world, building a more diverse and inclusive workforce, championing global health equity and more.

      “Lung cancer wasn’t even on my radar. Then I was diagnosed.”

      The disease is often detected late—which can have fatal consequences. But thanks to innovations in diagnostic tools, there’s a way to catch lung cancer earlier. Here’s how early detection saved one woman’s life.

      “I’m a scientist dedicated to bringing eye-health innovations to the world”

      Meet Xiao-Yu Song, Global Head of Research & Development for Vision at Johnson & Johnson, who leads a talented team that creates cutting-edge products addressing vision problems through all stages of life.

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      5 things we now know about bladder cancer

      Paradigm-shifting new therapies are helping people with the disease lead longer, more comfortable lives. For Bladder Cancer Awareness Month, learn how Johnson & Johnson is helping to change the treatment landscape.

      Press releases

      Late-breaking results show nipocalimab significantly improves Sjögren’s disease activity in a Phase 2 study

      Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren’s disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments

      TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

      24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study

      Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up

      RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median progression-free survival of 8.9 years1 Additional findings from pooled analysis of three Phase 3 studies showed treatment with ibrutinib has the potential to achieve comparable overall survival to the general European population2

      DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures

      System Will Utilize the SIGMA™ HP Partial Knee Implant, Which Demonstrated Improved 12-Year Survivorship Compared to Class

      Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX®

      If approved, PREZCOBIX® would offer a new HIV-1 treatment option for pediatric patients aged 6 and older weighing at least 25 kg

      More from Johnson & Johnson

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

      What is a gene mutation?

      Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. For DNA Day learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.

      Building climate-resilient health clinics

      When Mother Nature strikes—think triple-digit heatwaves, wildfires, hurricanes—vulnerable populations are at risk of missing out on much-needed healthcare. For Earth Day, learn how Johnson & Johnson is helping community clinics protect patients.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.